Insuman Basal Solostar (Insulin Human)

Insuman Basal Solostar is a basal insulin used to manage chronic hyperglycaemia in diabetes.

• Type 1 diabetes mellitus: provides long‑acting insulin to maintain fasting glucose levels.
• Type 2 diabetes mellitus: adds basal insulin to oral agents for improved glycaemic control.
• Insulin deficiency states (e.g., post‑pancreatectomy): supplies necessary basal insulin to replace endogenous production.

• Insulin human binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor tyrosine kinase pathway. This promotes translocation of GLUT‑4 transporters, increasing glucose uptake, and suppresses hepatic gluconeogenesis, thereby lowering blood glucose levels and providing basal metabolic control.

Insuman Basal Solostar may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects

• Hypoglycaemia: low blood glucose episodes, especially if dosing is excessive.
• Injection‑site reactions: redness, swelling, or itching at the injection site.
• Weight gain: increase in body weight associated with insulin therapy.
• Lipodystrophy: localized changes in fat tissue at repeated injection sites.

Serious or Rare Side Effects

• Anaphylactic reaction: severe allergic response requiring immediate medical attention.
• Severe hypoglycaemia with seizures or loss of consciousness.
• Insulin antibody formation: may alter insulin action and cause unpredictable glucose levels.
• Acute lipohypertrophy leading to erratic insulin absorption.

When using Insuman Basal Solostar, several precautions should be observed to ensure safe and effective therapy.

• Dose individualisation: adjust dose based on blood glucose monitoring and clinical response.
• Monitor hypoglycaemia: educate patients to recognise and treat low blood glucose promptly.
• Illness or stress: anticipate higher insulin requirements during infection or physiological stress.
• Renal or hepatic impairment: use caution and consider dose reduction in organ dysfunction.
• Concomitant medications: be aware of agents that may mask hypoglycaemia symptoms.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Basal Solostar can interact with other medicines, affecting glucose control or insulin action.

Major Interactions (Avoid)

• Concurrent use of other insulin products: risk of severe hypoglycaemia from additive insulin effect.
• Beta‑blockers: may mask typical hypoglycaemia symptoms such as tachycardia.
• Glucocorticoids: can markedly increase blood glucose, necessitating insulin dose adjustments.

Moderate Interactions (Monitor Closely)

• Sulfonylureas or other oral hypoglycaemics: additive glucose‑lowering effect may require dose reduction.
• Thiazide diuretics: may raise blood glucose levels, potentially requiring higher insulin dose.
• ACE inhibitors: may enhance insulin sensitivity, warranting closer glucose monitoring.